RxDoctor Payments Data

Jonas Rawlins, DO

Internal Medicine · Lynchburg, VANPI 1932441292

Payments from drug & device makers

$433in general payments, 2019–2025

Across 21 payments — averaging $20.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$140
  • Novo Nordisk$58
  • Boehringer Ingelheim$55
  • Novartis$39
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$27
  • GSK$23
  • plus $93 from 6 others

What the payments were for

  • Food & beverage$433100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$433 in reported general payments places this provider in the 65th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$49,721
Medicare patients
225
Services billed
532

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$7,937
Albuterol Sulfate HfaAlbuterol Sulfate26$655
Atorvastatin Calcium34$289
Duloxetine Hcl15$277
Levothyroxine Sodium18$223
Rosuvastatin Calcium18$194
Gabapentin18$149
Buspirone Hcl13$146
Amlodipine Besylate46$79
Losartan Potassium17$71
Azithromycin11$67
Lisinopril17$45
Hydrochlorothiazide14$41
Meloxicam15$23

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKAnoro Ellipta$23$7,93712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Lynchburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →